CF PharmTech, Inc. (H-share) reported the repurchase of 18,500 shares on 20 April 2026 under its existing mandate approved on 16 December 2025. The on-exchange purchases were executed within a price range of HK$22.48–22.86 per share, translating into a volume-weighted average cost of HK$22.63 and an aggregate outlay of HK$0.42 million.

Following the transaction, the company’s outstanding share base (excluding treasury shares) stands at 301.65 million, down from 301.67 million. Treasury shares increased to 0.57 million, while total issued shares remained unchanged at 302.22 million.

Since the current mandate commenced, CF PharmTech has repurchased 573,500 shares, equivalent to 0.19% of the issued share capital as at the mandate date and representing about 1.90% of the 30.22 million shares authorised for buyback.

All shares purchased on 20 April 2026 are being held as treasury stock; none have yet been cancelled. In line with Hong Kong Stock Exchange requirements, the company is subject to a moratorium on issuing or selling treasury shares until 20 May 2026.